Browse > Article
http://dx.doi.org/10.5352/JLS.2008.18.3.336

Induction of Apoptosis by HDAC Inhibitor Trichostatin A through Activation of Caspases and NF-κB in Human Prostate Epithelial Cells.  

Park, Cheol (Department of Biological Sciences, Pusan National University)
Jin, Cheng-Yun (Department of Biochemistry, Dongeui University College of Oriental Medicine and Department of Biomaterial Control (BK21 program), Dongeui University Graduate School)
Choi, Byung-Tae (Department of Anatomy, Graduate School of Oriental Medicine, Pusan National University)
Lee, Won-Ho (Department of Biological Sciences, Pusan National University)
Choi, Yung-Hyun (Department of Biochemistry, Dongeui University College of Oriental Medicine and Department of Biomaterial Control (BK21 program), Dongeui University Graduate School)
Publication Information
Journal of Life Science / v.18, no.3, 2008 , pp. 336-343 More about this Journal
Abstract
Histone deacetylases (HDACs) inhibitors have emerged as the accessory therapeutic agents for various human cancers, since they can block the activity of specific HDACs, restore the expression of some tumor suppressor genes and induce cell differentiation, cell cycle arrest and apoptosis in vitro and in vivo. In the present study, we investigated that the effect of trichostatin A (TSA), an HDAC inhibitor, on the cell growth and apoptosis, and its effect on the nuclear factor-kappaB $(NF-{\kappa}B)$ activity in 267B1 human prostate epithelial cells. Exposure of 267B1 cells to TSA resulted in growth inhibition and apoptosis induction in and dose-dependent manners as measured by fluorescence microscopy, agarose gel electrophoresis and flow cytometry analysis. TSA treatment inhibited the levels of IAP family members such as c-IAP-1 and c-IAP-2 and induced the proteolytic activation of caspase-3, -8 and -9, which were associated with concomitant degradation of poly (ADP-ribose)-polymerase, ${\beta}-catenin$ and laminin B proteins. The increase in apoptosis by TSA was connected with the translocation of $NF-{\kappa}B$ from cytosol to nucleus, increase of the DNA binding as well as promoter activity of $NF-{\kappa}B$, and degradation of cytosolic inhibitor of KappaB $(I{\kappa}B)-{\alpha}$ protein. We therefore concluded that TSA demonstrated anti-proliferative and apoptosis-inducing effects on 267B1 cells in vitro, and that the activation of caspases and $NF-{\kappa}B$ may play important roles in its mechanism of action. Although further studies are needed, these findings provided important insights into the possible molecular mechanisms of the anti-cancer activity of TSA.
Keywords
Histone deacetylases inhibitor; 267B1; apoptosis; caspase; nuclear factor-kappaB;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Peltonen, K., T. M. Kiviharju, P. M. Jarvinen, R. Ra and M. Laiho. 2005. Melanoma cell lines are susceptible to histone deacetylase inhibitor TSA provoked cell cycle arrest and apoptosis. Pigment Cell Res. 18, 196-202.   DOI   ScienceOn
2 Komata, T., T. Kanzawa, T. Nashimoto, H. Aoki, S. Endo, T. Kon, H. Takahashi, S. Kondo and R. Tanaka. 2005. Histone deacetylase inhibitors, N-butyric acid and trichostatin A, induce caspase-8- but not caspase-9-dependent apoptosis in human malignant glioma cells. Int. J. Oncol. 26, 1345-1352.
3 Kim, H. R., E. J. Kim, S. H. Yang, E. T. Jeong, C. Park, J. H. Lee, M. J. Youn, H. S. So and R. T. Park. 2006. Trichostatin A induces apoptosis in lung cancer cells via simultaneous activation of the death receptor-mediated and mitochondrial pathway? Exp. Mol. Med. 38, 616-624.   DOI   ScienceOn
4 Kim, Y. K., E. K. Lee, J. K. Kang, J. A. Kim, J. S. You, J. H. Park, D. W. Seo, J. W. Hwang, S. N. Kim, H. Y. Lee, H. W. Lee and J. W. Han. 2006. Activation of NF-kappaB by HDAC inhibitor apicidin through Sp1-dependent de novo protein synthesis: its implication for resistance to apoptosis. Cell Death Differ. 13, 2033-2041.   DOI   ScienceOn
5 Greenberg, V. L., J. M. Williams, J. P. Cogswell, M. Mendenhall and S. G. Zimmer. 2001. Histone deacetylase inhibitors promote apoptosis and differential cell cycle arrest in anaplastic thyroid cancer cells. Thyroid 11, 315-325.   DOI   ScienceOn
6 Kaufmann, S. H., S. Desnoyers, Y. Ottaviano, N. E. Davidson and G. G. Poirier. 1993. Specific proteolytic cleavage of poly (ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res. 53, 3976-3985.
7 Platta, C. S., D. Y. Greenblatt, M. Kunnimalaiyaan and H. Chen. 2007. The HDAC inhibitor trichostatin A inhibits growth of small cell lung cancer cells. J. Surg. Res. 142, 219-226.   DOI   ScienceOn
8 Philchenkov, A., M. Zavelevich, T. J. Kroczak and M. Los. 2004. Caspases and cancer: mechanisms of inactivation and new treatment modalities. Exp. Oncol. 26, 82-97.
9 Marks, P. A., V. M. Richon, T. Miller and W. K. Kelly. 2004. Histone deacetylase inhibitors. Adv. Cancer Res. 91, 137-168.   DOI   ScienceOn
10 Barisic, K., J. Petrik and L. Rumora. 2003. Biochemistry of apoptotic cell death. Acta. Pharm. 53, 151-164.
11 Baradari, V., A. Huether, M. Hopfner, D. Schuppan and H. Scherubl. 2006. Antiproliferative and proapoptotic effects of histone deacetylase inhibitors on gastrointestinal neuroendocrine tumor cells. Endocr. Relat. Cancer 13, 1237-1250.   DOI   ScienceOn
12 Antonsson, B. and J. C. Martinou. 2000. The Bcl-2 protein family. Exp. Cell Res. 256, 50-57.   DOI   ScienceOn
13 Pan, L. N., J. Lu and B. Q. Huang. 2007. HDAC Inhibitors: A potential new category of anti-tumor agents. Cell Mol. Immunol. 4, 337-343.
14 Fan, T. J., L. H. Han, R. S. Cong and J. Liang. 2005. Caspase family proteases and apoptosis. Acta. Biochim. Biophys. Sin. (Shanghai) 37, 719-727.   DOI   ScienceOn
15 Fulda, S. and K. M. Debatin. 2004. Apoptosis signaling in tumor therapy. Ann. N. Y. Acad. Sci. 1028, 150-156.   DOI   ScienceOn
16 Li, G. C., X. Zhang, T. J. Pan, Z. Chen and Z. Q. Ye. 2006. Histone deacetylase inhibitor trichostatin A inhibits the growth of bladder cancer cells through induction of p21WAF1 and G1 cell cycle arrest. Int. J. Urol. 13, 581-586.   DOI   ScienceOn
17 Kwon, O., K. A. Kim, S. O. Kim, R. Ha, W. K. Oh, M. S. Kim, H. S. Kim, G. D. Kim, J. W. Kim, M. Jung, C. H. Kim, J. S. Ahn and B. Y. Kim. 2006. NF-kappaB inhibition increases chemosensitivity to trichostatin A-induced cell death of Ki-Ras-transformed human prostate epithelial cells. Carcinogenesis 27, 2258-2268.   DOI   ScienceOn
18 LaCasse, E. C., S. Baird, R. G. Korneluk and A. E. MacKenzie. 1998. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 17, 3247-3259.   DOI   ScienceOn
19 Lee, C. H., Y. T. Jeon, S. H. Kim and Y. S. Song. 2007. NF-kappaB as a potential molecular target for cancer therapy. Biofactors 29, 19-35.   DOI   ScienceOn
20 Donadelli, M., C. Costanzo, L. Faggioli, M. T. Scupoli, P. S. Moore, C. Bassi, A. Scarpa and M. Palmieri. 2003. Trichostatin A, an inhibitor of histone deacetylases, strongly suppresses growth of pancreatic adenocarcinoma cells. Mol. Carcinog. 38, 59-69.   DOI   ScienceOn
21 Facchetti, F., S. Previdi, M. Ballarini, S. Minucci, P. Perego and C. A. La Porta. 2004. Modulation of pro- and anti- apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors. Apoptosis 9, 573-582.   DOI   ScienceOn
22 Rupinder, S. K., A. K. Gurpreet and S. Manjeet. 2007. Cell suicide and caspases. Vascul. Pharmacol. 46, 383-393.   DOI   ScienceOn
23 Yoshida, M., M. Kijima, M. Akita and T. Beppu. 1990. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J. Biol. Chem. 265, 17174-17179.
24 Schulze-Osthoff, K., D. Ferrari, M. Los, S. Wesselborg and M. E. Peter. 1998. Apoptosis signaling by death receptors. Eur. J. Biochem. 254, 439-459.   DOI   ScienceOn
25 Sarkar, F. H. and Y. Li. 2008. NF-kappaB: a potential target for cancer chemoprevention and therapy. Front. Biosci. 13, 2950-2959.   DOI
26 Wetzel, M., D. R. Premkumar, B. Arnold and I. F. Pollack. 2005. Effect of trichostatin A, a histone deacetylase inhibitor, on glioma proliferation in vitro by inducing cell cycle arrest and apoptosis. J. Neurosurg. 103, S549-S556.
27 Wylie, A. H., J. F. Kerr and A. R. Currie. 1980. Cell death: the significance of apoptosis. Int. Rev. Cytol. 68, 251-306.   DOI
28 Shetty, S., B. A. Graham, J. G. Brown, X. Hu, N. Vegh-Yarema, G. Harding, J. T. Paul and S. B. Gibson. 2005. Transcription factor NF-kappaB differentially regulates death receptor 5 expression involving histone deacetylase 1. Mol. Cell Biol. 25, 5404-5416.   DOI   ScienceOn
29 Vanhaecke, T., P. Papeleu, G. Elaut and V. Rogiers. 2004. Trichostatin A-like hydroxamate histone deacetylase inhibitors as therapeutic agents: toxicological point of view. Curr. Med. Chem. 11, 1629-1643.   DOI   ScienceOn
30 Rundall, B. K., C. E. Denlinger and D. R. Jones. 2004.Combined histone deacetylase and NF-kappaB inhibition sensitizes non-small cell lung cancer to cell death. Surgery 136, 416-425.   DOI   ScienceOn
31 Salvesen, G. S. and C. S. Duckett. 2002. IAP proteins: blocking the road to death's door. Nat. Rev. Mol. Cell. Biol. 3, 401-410.   DOI   ScienceOn
32 Ramsamooj, P., M. Kuettel, A. Dritschilo and M. Jung. 1997. p53-Independent tumorigenic progression of human prostate cells. Radiat. Oncol. Investig. 5, 269-274.   DOI   ScienceOn
33 Savickiene, J., G. Treigyte, V. Borutinskaite, R. Navakauskiene and K. E. Magnusson. 2006. The histone deacetylase inhibitor FK228 distinctly sensitizes the human leukemia cells to retinoic acid-induced differentiation. Ann. N. Y. Acad. Sci. 1091, 368-384.   DOI   ScienceOn